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Background. We described the clinical predictive role of emerging Escherichia coli O25b/sequence type 131
(ST131) in treatment failure of urinary tract infection.
Methods. In this prospective observational cohort study, the outpatients with acute cystitis with isolation of
E. coli in their urine cultures were assessed. All the patients were followed up for clinical cure after 10 days of treat-
ment. Detection of the E. coliO25:H4/ST131 clone was performed by multiplex polymerase chain reaction (PCR) for
phylogroup typing and using PCR with primers for O25b rfb and allele 3 of the pabB gene.
Results. In a cohort of patients with diagnosis of acute urinary cystitis, 294 patients whose urine cultures were
positive with a growth of >104 colony-forming units/mL of E. coli were included in the study. In empiric therapy,
ciprofloxacin was the first choice of drug (27%), followed by phosphomycin (23%), trimethoprim-sulfamethoxazole
(TMP-SMX) (9%), and cefuroxime (7%). The resistance rate was 39% against ciprofloxacin, 44% against TMP-SMX,
and 25% against cefuroxime. Thirty-five of 294 (12%) isolates were typed under the O25/ST131 clone. The clinical
cure rate was 85% after the treatment. In multivariate analysis, detection of the O25/ST131 clone (odds ratio [OR], 4;
95% confidence interval [CI], 1.51–10.93; P = .005) and diabetes mellitus (OR, 2.1; 95% CI, .99–4.79; P = .05) were
found to be significant risk factors for the treatment failure. In another multivariate analysis performed among quin-
olone-resistant isolates, treatment failure was 3 times more common among the patients who were infected with
ST131 E. coli (OR, 3; 95% CI, 1.27–7.4; P = .012).
Conclusions. In urinary tract infections, the E. coli ST131 clone seems to be a consistent predictor of treatment
failure.
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Urinary tract infection (UTI) is one of the most com-
mon bacterial infections, with a high global burden
[1]. Patients with UTI are frequently given empiric
therapy, and successful treatment has become more dif-
ficult because of the rapid spread of antibiotic resis-
tance. Escherichia coli is the most common causative
agent of acute cystitis, and fluoroquinolones are the
most commonly prescribed class for empiric treatment
of UTI [1, 2]. Over the last decade, the E. coli sequence
type 131 (ST131) clone has emerged as an important
human pathogen worldwide and is recognized as a pan-
demic clone [3–5]. It has been shown that E. coli strains
in the ST131 group, in addition to being resistant to
most β-lactam antibiotics, are frequently resistant to
aminoglycosides and fluoroquinolones [6]. The ST131
clone is strongly associated with extended-spectrum
β-lactamases (ESBLs), predominantly the CTX-M-15
type [4, 7]. Emergence of the ST131 clone posed a sig-
nificant threat to human health because of its combina-
tion of successful spread, capability to withstand the
effect of various antimicrobial agents, and possession
of high numbers of virulence factors [3].
The emergence of ST131 strains has made UTI
management more problematic, leading to discordant
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antimicrobial therapy and increased morbidity and mortality
[8]. Although there are well-designed studies about emerging
epidemiology of ST131, to our knowledge the most important
mechanisms of transmission and risk factors are not clearly un-
derstood. Moreover, clinical outcome of uropathogenic E. coli
ST131 infections has not yet been reported. In this study, we
aimed to describe the risk factors for treatment failure in
acute cystitis and to detect the clinical impact of E. coli ST131
and other potential parameters.
MATERIALS AND METHODS
Study Population
Urine samples were collected from consecutive outpatients with
acute cystitis who had at least 1 UTI symptom, such as fever,
urgency, hematuria, and dysuria, in 2011 at the outpatient clin-
ics of Baskent University Hospital in Ankara, Turkey. Among
these patients, urine analyses were done and urine samples
were cultured. Those patients who had E. coli isolated from
their urine were included in the study. Empiric antibiotic treat-
ment was started after collection of urine samples for urine
analysis and culture testing. According to the susceptibility
test results, the empiric treatment regimen was switched to an
appropriate choice, if resistance was detected. Empiric antibiot-
ics, and patient’s age, sex, history of hospitalization and antibi-
otic use, catheterization, and comorbidities were recorded. All
the patients were followed up by outpatient visits, if not possible
by phone calls, for clinical cure 10 days after the start of the
treatment. Failure of the treatment was defined as persistence
of the symptoms after 10 days of treatment or detection of re-
sistance to empiric antibiotic and switching to the appropriate
choice. This study was approved by the institutional review
board of Baskent University with the project number of
KA11/107 and the decision number of 11/87.
Susceptibility Testing
Susceptibility testing to 23 antibiotics (ampicillin, cefazolin,
gentamicin, amikacin, ampicillin-sulbactam, amoxicillin-
clavulanic acid, piperacillin-tazobactam, cefuroxime, cefepime, ce-
foxitin, trimethoprim-sulfamethoxazole [TMP-SMX], ceftriaxone,
ciprofloxacin, levofloxacin, imipenem, meropenem, ertapenem,
aztreonam, ceftazidime, cefotaxime, norfloxacin, nitrofurantoin,
and fosfomycin) was performed by disk diffusion method accord-
ing to Clinical and Laboratory Standards Institute (CLSI) guide-
lines [9]. Escherichia coli multidrug resistance was defined as
resistance to 1 or more agents in ≥3 classes of antibiotics.
ESBL production was evaluated according to CLSI criteria
[9]. The β-lactamase–producing isolates were searched for
CTX-M positivity by polymerase chain reaction (PCR), as
described previously [10]. Isolates belonging to CTX-M group
1 were further analyzed for CTX-M-15–type lactamase
by sequencing. Sequences were compared with those deposited
in the National Center for Biotechnology Information database.
In phylogenetic analysis, the ChuA and Yja A genes and
TspE4.C2 fragments of DNA were examined by multiplex
PCR [11]. Detection of O25b/ST131 clonal group was done
by PCR using primers for O25b rfb and allele 3 of the pabB
gene, described previously [3]. To confirm these clonal assign-
ments, selected isolates underwent multilocus sequence typing
based on a protocol published on the University College Cork
website (http://mlst.ucc.ie/mlst/). The partial sequences of 7
housekeeping genes were compared: adk, fumC, recA, mdh,
purA, gyrB, and icd. DNA sequences were assembled and mul-
tiple alignment analyses were performed by using Applied
Maths version 7.0, BioNumerics. The sequencing analyses con-
firmed the PCR typing of ST131 isolates.
Statistical Analysis
Comparisons of categorical variables were tested by χ2 test,
and continuous variables by t test. Univariate and multi-
variate analyses for the prediction of the risk factors of
treatment failure were determined by logistic regression analy-
sis. Independent variables related to patient risk factors and vir-
ulence factors were included in the model. The independent
variables were age >60 years, antibiotic use within last 3 months,
hospitalization within last year, surgery within last year, chronic
heart disease, diabetes mellitus, chronic renal failure, ST131
clone, quinolone resistance, ESBL production, and multi-
drug resistance. Statistical analyses was performed using
Stata software version 11, and statistical significance was set at
P < .05.
RESULTS
In a cohort of patients with diagnosis of acute urinary cystitis,
294 patients whose urine cultures were positive with a growth of
>104 colony-forming units/mL of E. coli were included in the
study. In empiric therapy, ciprofloxacin was the first choice of
drug (27%), followed by phosphomycin (23%), TMP-SMX
(9%), and cefuroxime (7%). The resistance rate was 39% against
ciprofloxacin, 44% against TMP-SMX, and 25% against cefur-
oxime. No resistance was detected against phosphomycin and
carbapenems. Resistance to ≥3 different groups of antibiotics
(β-lactams, aminoglycosides, quinolones, TMP-SMX) was de-
fined as multidrug resistance and was detected in 107 (36%)
E. coli isolates. ESBL producers accounted for 70 of 294
(24%) isolates. CTX-M-15 β-lactamase was detected in 40 iso-
lates (14%). Thirty-five of 294 (12%) isolates were typed under
the ST131 clone. In univariate analysis, use of quinolones and
antibiotics other than quinolones within the last 3 months, hos-
pitalization within last year, surgery within last year, multidrug
resistance, ESBL production, and CTX-M-15 positivity were
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found to be significantly associated risk factors of infection by
strain of the ST131 clone (Table 1).
The clinical cure rate was 85% after treatment. Treatment fail-
ure was significantly increased with quinolone use within last 3
months, hospitalization within last year, operation within last
year, quinolone resistance, multidrug resistance, CTX-M-15
positivity, belonging to the ST131 clone, and ESBL production
(Table 2). Statistically significant variables in univariate analysis
were included in the multivariate analysis, and having diabetes
mellitus and detection of the ST131 clone were found to be sig-
nificant risk factors for treatment failure (Table 3).
Another multivariate analysis was performed among quino-
lone-resistant isolates for prediction of treatment failure. In this
analysis, none of the risk factors, except belonging to the ST131
group, were found to be significant on treatment failure. Treat-
ment failure was 3 times more common among the patients
who were infected with ST131 E. coli than the patients who
were infected with non-ST131 group (odds ratio [OR], 3.0;
95% confidence interval [CI], 1.27–7.4; P = .012). Among quin-
olone-resistant E. coli isolates, CTX-M-15 positivity was more
common among ST131 isolates (38%) than non-ST131 isolates
(19%) (P = .029).
DISCUSSION
UTIs due to E. coli cause considerable morbidity and morta-
lity, and management is complicated by the increasing preva-
lence of antimicrobial resistance [4, 12]. Empiric treatment of
UTIs became a difficult clinical problem, primarily because of
increasing fluoroquinolone resistance in E. coli [13, 14]. Recent-
ly, a highly resistant clone of E. coli, ST131, was reported to be a
global dominating clone in extraintestinal E. coli infections [4, 5,
15, 16]; however, clinical implications were not clearly defined.
By this prospective clinical observational study among patients
with acute urinary cystitis, we investigated independent risk fac-
tors, including ST131, related to the host and the pathogen that
could have an effect on treatment failure.
The clinical cure rate was 85% after the treatment. In multi-
variate analysis, the failure was 4 times more common among
the patients who had UTI with ST131 E. coli than the patients
infected with non-ST131 isolates (OR, 4.0; 95% CI, 1.51–10.93;
P = .005; Table 3). According to 1 retrospective study including
300 patients, cure rates and mortality did not differ between pa-
tients with ST131 vs non-ST131 E. coli infections [15]. Another
study performed among 100 patients with E. coli bacteremia did
not find an effect of the ST131 clone on fatality. For detection of
such an effect of ST131 on fatality, a bigger sample size is need-
ed. We demonstrated the impact of the ST131 clone as an inde-
pendent factor on treatment failure, by controlling the potential
confounding parameters. As Banerjee et al indicated, retrospec-
tive studies might be biased by the selection of the infected or
colonized patients [15]. One of the strong points of our study
was being prospective, which yielded precise discrimination of
colonized and infected patients.
This study was performed in a region where fluoroquinolone
resistance is >20% [13]. To describe the role of the ST131 clone
Table 1. Risk Factors for Presence of Sequence Type 131 Clone
Risk Factor
ST131
Isolates
(n = 35),
No. (%)
Non-ST131
Isolates
(n = 259),
No. (%)
P
Value
Patient risk factors
Mean age (SD) 50 (17) 53 (20) .318
Female sex 31 (89) 221 (85) .607
Antibiotic use other than
quinolones within last 3 mo
10 (29) 55 (21) .345
Quinolone use within last 3 mo 13 (37) 48 (19) .011
Hospitalization within the last
year
16 (46) 60 (23) .004
Operation within the last year 11 (31) 34 (13) .005
Bacterial factors
Quinolone resistance 42 (100) 79 (31) <.001
Multidrug resistance 26 (74) 81 (31) <.001
ESBL production 21 (60) 49 (19) <.001
CTX-M-15 positivity 13 (37) 27 (10) <.001
Abbreviations: ESBL, extended-spectrum β-lactamase; SD, standard deviation;
ST131, sequence type 131.
Table 2. Univariate Analysis for Treatment Failure
Risk Factor
Treatment
Failure
(n = 35),
No. (%)
No Treatment
Failure
(n = 259),
No. (%)
P
Value
Patient risk factors
Mean age (SD) 56 (17) 53 (20) .277
Female sex 39 (87) 213 (86) .843
Antibiotic use within last
3 mo
26 (58) 100 (41) .033
Quinolone use within last
3 mo
12 (27) 49 (20) .287
Hospitalization within last
year
19 (42) 57 (23) .006
Operation within last year 13 (29) 32 (13) .006
Bacterial factors
Quinolone resistance 28 (62) 86 (35) <.001
Multidrug resistance 30 (54) 86 (28) <.001
Belonging to ST131 clone 14 (31) 21 (8) <.001
ESBL production 17 (38) 53 (21) .017
CTX-M-15 positivity 10 (22) 30 (12) .067
Abbreviations: ESBL, extended-spectrum β-lactamase; SD, standard deviation;
ST131, sequence type 131.
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in treatment failure of infections with fluoroquinolone-resistant
isolates (n = 114), we performed another multivariate analysis,
including the entire host and bacterial risk factors. Among
quinolone-resistant isolates, treatment failure was 3 times more
common among the patients who were infected with ST131
E. coli than among those in the non-ST131 group (OR, 3; 95%
CI, 1.27–7.4; P = .012). Detection of ST131 as a significant fac-
tor in both analyses overall and in the quinolone-resistant group
enhances the predictive role of ST131 on treatment failure, as an
independent strong parameter. It is also possible that the higher
virulence of the ST131 clone because of adherence to urinary
tract epithelial cells and persistence may explain the treatment
failure among the patients infected with ST131 clones [17]. In
regions where fluoroquinolone resistance is >20%, they are not
suggested as the first choice in empiric treatment [14]; however,
in our study, we found that fluoroquinolones were the first
choice in empiric treatment. In UTI, resistance rates against
antibiotics is high and there are limited alternatives to fluoroquin-
olones in treatment. Because there are few alternatives to fluoro-
quinolones in UTI, and overall resistance rate against all the
antibiotics was high. Therefore, detection of the ST131 clone
could be important by using rapid diagnostic tools such as matrix-
assisted laser desorption/ionization mass spectrometry [18, 19].
Overall, 35 of 294 (12%) isolates were typed under the ST131
clone; recently, ST131 was detected in 10%–27% of E. coli iso-
lates in various studies [4, 20, 21]. The rate of ESBL, predomi-
nantly CTX-M-15 positivity, was found to be higher in the
ST131 clone compared with non-ST131 isolates (60% vs 19%,
P < .001; Table 1). Our result was in parallel with some reports
[22], but in other studies, the ST131 clone was reported to be
higher in non-ESBL-producing E. coli [3]. This could be related
to the high diversity of the ST131 clone, as with other E. coli
clones. The presence of CTX-M-15 is significantly associated
with resistance to first choice of antibiotics of empiric therapy
(quinolones and β-lactams), and may favor a selection pressure
for the CTX-M-15–containing strains [17]. Detection of high
rate of CTX-M-15 in the ST131 clone might help us to predict
the increasing rate of treatment failure proportional to the in-
creasing rate of ST131 among other E. coli clones. In the
ST131 clone, the multidrug resistance rate was 74% (P < .001),
which was reported as 70% in another study [23]. The rate of
TMP-SMX resistance was 71% (P < .001) in the ST131 clone;
however, it was 56% in another report [23]. In our study, all
ST131 isolates were quinolone resistant. In conclusion, in
UTIs, the E. coli ST131 clone seems to be a consistent predictor
of treatment failure, which was directly related to rapidly emerg-
ing global resistance. Early and rapid detection of E. coli ST131
may be useful in management of UTI.
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